ghazal vakilzadeh

Artificial Intelligence (AI) has transformed the realm of disease diagnosis, providing unparalleled accuracy and efficiency. By utilizing sophisticated algorithms and extensive data sets, AI systems can uncover patterns that are imperceptible to the human eye. These systems enhance diagnostic precision, minimize human errors, and enable early identification of ailments, which is crucial for favorable treatment results. AI's capabilities span diverse medical imaging modalities like MRI, CT scans, and X-rays, aiding in the detection of abnormalities such as tumors or fractures. Furthermore, AI assists pathologists by scrutinizing tissue samples for disease indicators at a cellular level. The incorporation of AI into diagnostic procedures not only expedites decision-making but also individualizes patient care by predicting specific disease risks and proposing customized treatment strategies. As AI technology progresses, its potential to revolutionize healthcare and enhance patient outcomes becomes increasingly apparent. This article succinctly examines the role of artificial intelligence in disease diagnosis.

Colorectal cancer (CRC) is positioned as the third most widespread form of cancer on a global scale, affecting both males and females. Furthermore, it holds the unfortunate title of being the second leading cause of deaths associated with cancer, and it remains the primary contributor to mortality in cases of gastrointestinal cancer. CRC specifically affects the colon and rectum, resulting from the abnormal growth of glandular epithelial cells in the colon. CRC treatment options encompass a range of interventions such as surgical procedures, radiation therapy, chemotherapy, and additional modalities. However, these treatments often come with side effects that can make the patient's journey exhausting. Therefore, there is a pressing need for new treatment approaches that can minimize these side effects. In recent years, oncolytic viruses have gained substantial attention from researchers as a promising approach in the field of cancer treatment. However, there have been obstacles to overcome, such as the immune system's interference, preventing the oncolytic virus from functioning effectively and neutralizing it before it reaches the tumor. To address this challenge, a carrier is required to ensure safe delivery of the virus to the tumor site. Mesenchymal cells have emerged as potential candidates for facilitating virus transmission due to their favorable properties as carriers. In this article, we delve into the application of mesenchymal cells as carriers for Newcastle Oncolytic Virus in the treatment of colorectal cancer. Our objective through this research is to make significant contributions to the advancement of novel and enhanced methodologies in combating this particular disease.

Varicella Zoster Virus (VZV) is an alpha herpes virus that can conceal itself and produce shingles in addition to generating chicken pox. Varicella is a highly contagious illness brought on by vesicular skin sores, contamination, and maybe to a lesser extent, the propagation of the aerosolized virus. In comparison to children, adults with varicella had a much higher rate of primary VZV infection death. Different nations produce the varicella vaccines known as (Varivax; ProQuad; Merck & Co.), (Varilrix; Priorix-tetra; GSK), (Okavax; Biken, by Sanofi Pasteur), and (SuduVax; Green Cross). The amount of HDC passes, specific antibiotics included to assure sterility, stabilizers, and other minor components vary between different vaccines. The spread of the virus can be decreased dramatically by the widespread use of the varicella vaccine, particularly in a worldwide vaccination program. The World Health Organization suggested varicella vaccination in 1998 for nations where the illness poses a serious threat to public health. Nevertheless, many nations delayed the introduction of the universal varicella vaccine due to worries about the disease spreading to older populations, an increase in elderly herpes zoster, and cost-effectiveness. The purpose of the current research is to review varicella vaccination programs and their global effect.